Ionis Pharmaceuticals Introduces Breakthrough ION582 for the Treatment of Angelman Syndrome
Ionis Pharmaceuticals has introduced ION582 as an investigational therapy that has received FDA Breakthrough Therapy Designation for the treatment of Angelman syndrome (AS), a rare neurological disorder.
ION582 is an RNA-targeted antisense medicine designed to inhibit the UBE3A antisense transcript (UBE3A-ATS) and increase production of the UBE3A protein. By restoring UBE3A expression, the therapy aims to address the underlying cause of Angelman syndrome and improve key functional domains such as communication, cognition, and motor skills.
The FDA Breakthrough Therapy Designation highlights the potential of ION582 to provide meaningful clinical benefits for individuals with AS, a condition for which no disease-modifying treatments currently exist. The designation is based on promising results from the Phase 1/2 HALOS study, which demonstrated consistent improvement across multiple functional measures along with favourable safety and tolerability.
Angelman syndrome is a rare genetic disorder, affecting approximately 1 in 21,000 people worldwide. The condition results from loss of function of the maternal UBE3A gene. Individuals with AS have a normal lifespan but often require full-time care due to intellectual, motor, and communication impairments. Existing therapies only manage some symptoms, leaving a clear need for treatments that target the underlying disease.
ION582 is the first investigational therapy to receive U.S. FDA Breakthrough Therapy designation for the treatment of Angelman syndrome, offering a potential disease-modifying option for individuals living with this rare neurological disorder.
